{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:13Z","timestamp":1793228113014,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration. The UK was an early adopter of SC daratumumab and, as such, this report provides consensus recommendations from a group of UK MM experts, with the aim of facilitating the transition from IV to SC daratumumab for other European healthcare providers. The switch from IV to SC daratumumab has been beneficial to patients and healthcare providers, as it simplifies treatment, reduces pressure on hospitals and can improve patients\u2019 quality of life.<\/jats:p>","DOI":"10.3389\/fonc.2023.1063144","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T07:42:34Z","timestamp":1677138154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers"],"prefix":"10.3389","volume":"13","author":[{"given":"Gordon","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Henshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Tailor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S212526","article-title":"Evaluating daratumumab in the treatment of multiple myeloma: Safety, efficacy and place in therapy","volume":"12","author":"Dima","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B2","article-title":"DARA SC prescribing information","volume-title":"DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use. prescribing information","year":"2022"},{"key":"B3","article-title":"DARA SC summary of product characteristics","volume-title":"DARZALEX\u00ae 1,800 mg solution for injection. summary of product characteristics","year":"2022"},{"key":"B4","article-title":"DARA IV summary of product characteristics","volume-title":"DARZALEX\u00ae 20 mg\/mL concentrate for solution for infusion. summary of product characteristics","year":"2022"},{"key":"B5","article-title":"DARA IV prescribing information","volume-title":"DARZALEX\u00ae (daratumumab) injection, for intravenous use. prescribing information","year":"2022"},{"key":"B6","article-title":"Optimizing daratumumab infusion: Assessing the safety and feasibility of omitting preinfusion medications and decreasing infusion time","volume":"11","author":"Preedit","year":"2021","journal-title":"J Hematol Oncol Pharm"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.851864","article-title":"Safety of rapid daratumumab infusion: A retrospective, multicenter, real-life analysis on 134 patients with multiple myeloma","volume":"12","author":"Bonello","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.570187","article-title":"Long-term safety of rapid daratumumab infusions in multiple myeloma patients","volume":"10","author":"Gozzetti","year":"2020","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243790","article-title":"Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)","volume":"106","author":"San-Miguel","year":"2021","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study","volume":"192","author":"Chari","year":"2021","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03365-w","article-title":"Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results","volume":"147","author":"Usmani","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S302682","article-title":"Results of a time and motion survey regarding subcutaneous versus intravenous administration of daratumumab in patients with relapsed or refractory multiple myeloma","volume":"13","author":"Slavcev","year":"2021","journal-title":"Clinicoecon Outcomes Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"Anderson","year":"2019","journal-title":"Future Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous injection of drugs: Literature review of factors influencing pain sensation at the injection site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1182\/blood-2021-149012","article-title":"Clinical administration characteristics of subcutaneous and intravenous administration of daratumumab in multiple myeloma patients at Mayo clinic","volume":"138","author":"Soefje","year":"2021","journal-title":"Blood"},{"key":"B17","article-title":"Daratumumab infusion reaction rates pre- and post-addition of montelukast to pre-medications","volume":"29","author":"Coffman","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.05.024","article-title":"Evaluation of montelukast for the prevention of infusion-related reactions with daratumumab","volume":"20","author":"Moore","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.esmoop.2020.100007","article-title":"Flexible care in breast cancer","volume":"6","author":"Wardley","year":"2021","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: An overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1063144\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T07:42:39Z","timestamp":1677138159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1063144\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":20,"alternative-id":["10.3389\/fonc.2023.1063144"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1063144","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"1063144"}}